title: [Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
abstract: BACKGROUND
  Eicosapentaenoic acid-enriched oral nutritional supplements (Prosure®; Abbott Japan, Tokyo, Japan) may attenuate surgical stress and catabolism after gastric cancer surgery. The present study aimed to evaluate the effects of Prosure® on body weight loss( BWL) and compliance with S-1 adjuvant chemotherapy after gastrectomy.
  
  
  METHODS
  Patients who underwent curative total gastrectomy for gastric cancer were selected to undergo adjuvant S-1 chemotherapy at Kanagawa Cancer Center between December 2010 and October 2011. The patients received a normal postgastrectomy diet and two 240 mL packs of Prosure® for 21 postoperative days. BWL was defined as %BWL and calculated as %BWL=(preoperative body weight-1-month postoperative body weight)×100/preoperative body weight. Time to S-1 treatment failure was calculated.
  
  
  RESULTS
  Five patients were enrolled in this study. The median age was 62.0 years. One patient was male, and 4 were female. The 1-month postoperative BWL was 92.1%. Compared to our previous report, a 20% risk reduction was observed in this study (Prosure® group vs control group, 92.1% vs 89.7%). Moreover, all the patients continued with the S-1 adjuvant chemotherapy for longer than 6 months.
  
  
  CONCLUSIONS
  Prosure® may inhibit BWL at 1 month after gastrectomy. Moreover, Prosure® improved the patients' compliance with the adjuvant chemotherapy after gastrectomy.
authors.affiliation: Dept. of Gastrointestinal Surgery, Kanagawa Cancer Center.
authors.forename: Toru
authors.initials: T
authors.lastname: Aoyama
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Hayashi
authors.forename: Hirohito
authors.initials: H
authors.lastname: Fujikawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogata
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Cho
authors.forename: Hiroo
authors.initials: H
authors.lastname: Wada
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kitani
authors.forename: Norio
authors.initials: N
authors.lastname: Yukawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Oshima
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Ozawa
authors.forename: Munetaka
authors.initials: M
authors.lastname: Masuda
authors.forename: Takaki
authors.initials: T
authors.lastname: Yoshikawa
mesh_terms: D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D004750:Enteral Nutrition; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005641:Tegafur / Q000009:adverse effects* / Q000627:therapeutic use; D015431:Weight Loss
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D015118:Eicosapentaenoic Acid